Brief Title
Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey
Official Title
Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey
Brief Summary
Retrospective review of 5-year long term outcomes of superselective intra-arterial chemotherapy treatment in retinoblastoma in a single institute. The treatment outcomes, globe salvage rates and complications of superselective intra-arterial chemotherapy both for treating naive patients (primary treatment group) and for patients who received systemic chemotherapy previously (secondary treatment group) were evaluated.
Study Type
Observational
Primary Outcome
globe salvage
Condition
Retinoblastoma
Intervention
intra-arterial administration of melphalan
Study Arms / Comparison Groups
group 1
Description: Patients who received intra-arterial chemotherapy as a first line treatment
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
30
Start Date
August 30, 2016
Completion Date
November 30, 2016
Primary Completion Date
November 30, 2016
Eligibility Criteria
Inclusion Criteria: - patients diagnosed with unilateral/bilateral retinoblastoma Exclusion Criteria: - patients with trilateral retinoblastoma - extraoculer involvement - patients with blood dyscrasias, bleeding and clotting disorders
Gender
All
Ages
5 Months - 7 Years
Contacts
, ,
Location Countries
Turkey
Location Countries
Turkey
Administrative Informations
NCT ID
NCT03935074
Organization ID
10136532
Responsible Party
Principal Investigator
Study Sponsor
Istanbul University-Cerrahpasa
Study Sponsor
, ,
Verification Date
May 2019